180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
Yahoo! Finance
PALO ALTO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company has engaged Kinexum, a strategic advisory firm, to support the Company in submitting a Marketing Authorisation Application (MAA) for adalimumab to treat progressive early-stage Dupuytren’s disease. The MAA will be submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA or Agency). As part of the ap
Continue Reading